Summary of Key Points Core Viewpoint - The company reported a shareholder loss of approximately $2.215 million for the six months ending June 30, 2025, compared to a loss of about $2.621 million in the same period last year [1] Group 1: Financial Performance - The company's shareholder loss decreased from $2.621 million to $2.215 million year-on-year [1] Group 2: Product Development - The main goal of Jiangsu Wanbang Pharmaceutical is to obtain market approval for Senstend™ in China by the end of 2025, with expectations for commercial launch in the first quarter of 2026 [1] - If the National Medical Products Administration grants an import license for Senstend™, Jiangsu Wanbang Pharmaceutical will need to pay the group $5 million (before Chinese withholding tax) [1] - After the first commercial sale of Senstend™ in China, Jiangsu Wanbang Pharmaceutical will owe the group an additional $2 million (before Chinese withholding tax) [1] Group 3: Clinical Research - The company has evaluated proposals from two well-known clinical research institutions regarding the Phase III clinical study of Fortacin™ in the United States and is in discussions with several pharmaceutical companies about licensing Fortacin™ in the U.S. market [1]